← Back to all signals
RESEARCH PAPER ANALYSIS

Respiratory-Swallow Training and Variable Practice in Parkinson's Disease: A Clinical Trial Pilot Study.

Pilot randomized clinical trial in 12 people with Parkinson’s found that exhale-swallow-exhale respiratory-swallow training increased exhale-swallow-exhale usage and, particularly with variable practice, improved swallowing safety and efficiency (less residue and lower penetration-aspiration…

PMID42048271
JournalFolia phoniatrica et logopaedica : official organ of the International Association of Logopedics and Phoniatrics (IALP)
Publication Date2026-04-28
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Pilot randomized clinical trial in 12 people with Parkinson’s found that exhale-swallow-exhale respiratory-swallow training increased exhale-swallow-exhale usage and, particularly with variable practice, improved swallowing safety and efficiency (less residue and lower penetration-aspiration…

WHY IT MATTERS

Research significance

Provides clinically actionable evidence for a non-pharmacologic rehabilitation method that may reduce aspiration risk and improve quality of life in PwPD and guides design of larger confirmatory trials, though it has limited direct implication for molecular or disease-modifying therapeutic…

ABSTRACT

Source abstract

PURPOSE: Dysphagia in people with Parkinson's disease (PwPD) is closely linked to impairments in respiratory-swallow coordination. Respiratory-swallow training (RST) is a promising, mechanism-based intervention for dysphagia, but to date, only a single-subject study has examined RST in PwPD. As an early-stage next step in refining RST for PwPD, this clinical trial pilot study aimed to: (1) explore the preliminary associations between exhale-swallow-exhale RST and swallowing safety, swallowing efficiency, and respiratory phase patterning; and (2) explore differences in practice structure (constant vs. variable practice) on RST-related motor learning outcomes. METHOD: PwPD completed pre-RST assessments, four once-weekly sessions of RST targeting only the exhale-swallow-exhale pattern, and post-RST assessments. Participants were randomized to constant practice or variable practice training conditions. Outcomes were measured using nasal airflow, respiratory inductive plethysmography, submental surface electromyography, and FEES. Multilevel statistical models were used to evaluate changes in exhale-swallow-exhale usage, pharyngeal residue, penetration, and aspiration. RESULTS: 12 PwPD completed all study phases, yielding an analysis of 1,565 swallows. In this pilot sample, exhale-swallow-exhale usage was higher post-RST compared to pre-RST (p < .05), with exhale-swallow-exhale usage observed to be higher at 1-month follow-up in the variable practice group compared to the constant practice group (p < .05). Additionally, pharyngeal residue, laryngeal vestibule residue, vocal fold residue, and Penetration-Aspiration Scale scores were lower post-RST compared to pre-RST (p < .05), (p < .05). CONCLUSIONS: This clinical trial pilot study provides preliminary evidence that RST may be associated with increased exhale-swallow-exhale usage, swallowing safety, and swallowing efficiency in PwPD. Preliminary evidence also suggests that variable practice may enhance retention and generalization of exhale-swallow-exhale usage, warranting further evaluation. Findings from this study will be used to inform refinement of RST for PwPD and the design of future confirmatory randomized clinical trials.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic